Our Mission

Halo is exploiting novel insights in ECM biology by selectively modulating its components to address diseases with high unmet need that are driven by inflammation and fibrosis 

We are building a differentiated pipeline based on novel insights into how dysregulation of the ECM  drives disease.

Alterations to the ECM are associated with a variety of conditions including pulmonary hypertension, lung fibrosis, liver fibrosis, and diabetes.